Trial Profile

Phase II trial of anetumab ravtansine (BAY 94-9343) in patients with advanced or metastatic malignant pleural mesothelioma (MPM) overexpressing mesothelin after first line treatment with platinum in combination with pemetrexed

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 26 Jul 2016

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

12 Mar 2016 There is one more trial (CTP 263551) similar to this trial.Trial data reported in CTP 263551 reports about BAY 94-9343 as primary drug and Vinorelbine as active comparator, as reported per EudraCT and CT.gov sources. But UKCRN 19468 record does not mention about use of "Vinorelbine" in trial.So as of now I have created this record. In future, if any amendment in UKCRN record (269009) suggests use of "Vinorelbine" this CTP(269009) need to be merged with CTP (263551).
12 Mar 2016 New trial record

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com